

- (i) an antineoplastic alkylphospholipid,
 (ii) an antineoplastic water -or lipid-soluble antiestrogen associated in
 liposomal form with said antineoplastic alkylphospholipid,
 (iii) a nonneoplastic phospholipid, and
 optionally one or more of (iv) a sterol, (v) a positively or negatively
 charged lipid, and (vi) a PEG lipid.--

-- 11. The composition of claim 10, wherein said alkylphospholipid has the
 formula



wherein

R is a C₁₂₋₂₂ alkyl, alkenyl, or alkynyl residue,

Y is oxygen, sulfur, or a CH₂ residue,

P is a PO₂ residue, and

X is a choline, or modified choline residue, or serine, ethanolamine, or
 glycerine group, or a synthetic modification thereof. --

-- 12. The composition of claim 10, wherein said alkylphospholipid is
 hexadecylphosphocholine, octadecylphosphocholine, erucylphosphocholine,
 octadecyl-[2-(N-methylpiperidino)ethyl]phosphate,

4 octadecylphosphoethanolamine, or hexadecyl-phosphoserine.--

1 -- 13. The composition of claim 10, wherein said antiestrogen is tamoxifen,
2 droloxifen, toremifen, idoxiphen, raloxiphen, miproxiphen-phosphate (TAT-59),
3 ICI 164,3384, ICI 182,780, a main metabolite of tamoxiphen, 4-hydroxy tamoxi-
4 phen, N-desmethyltamoxiphen.--

1 -- 14. The composition of claim 10, wherein said nonneoplastic
2 phospholipid is a naturally occurring or synthetic material, with a lipid :
3 antiestrogen molar ratio of between 0-10 : 1 (m/m). --

1 -- 15. The composition of claim 14, wherein said nonneoplastic
2 phospholipid is phosphocholine, serine, ethanolamine, glycerol.--

1 -- 16. The composition of claim 10, wherein said sterol is cholesterol, or
2 sitosterol in a sterol : alkylphospholipid molar ratio of 0-1 : 1.--

1 -- 17. The composition of claim 10, wherein said PEG lipid is N-(O-
2 methoxy-polyethyleneglycyl)-1,2-distearyl-s,n-glycero-3-phosphoethanolamine
3 (PEG₂₀₀₀ -